Neurology News

Veterans who were paired with service dogs demonstrated lower PTSD symptom severity, anxiety and depression, a study published in JAMA Network Open showed.

SAN DIEGO — Concurrent use of atogepant for preventive treatment of episodic migraine and ubrogepant for acute migraine treatment was safe and well-tolerated at 12 weeks, according to a study.

The AMA adopted policies to protect patients’ access to necessary health care in a variety of ways at its annual meeting.

In a phase 2/3 clinical trial, treatment with buntanetap was linked to cognitive gains as well as tau reduction at 12 weeks in those exhibiting mild to moderate symptoms of Alzheimer’s disease, according to the drug’s manufacturer.

The FDA has approved an abbreviated new drug application for a generic version of Emflaza to treat Duchenne muscular dystrophy, according to the manufacturer.

The AMA adopted new policies on broader Medicare and Medicaid health care coverage during its annual House of Delegates meeting.

DENVER — Patients with idiopathic hypersomnia have higher odds of comorbidities both related and unrelated to sleep, Jed Black, MD, says in this Healio video from the American Academy of Neurology annual meeting.

The AMA announced a new policy that supports requirements for drug and device sponsors to develop diversity action plans so that women and sexual and gender minorities are adequately represented in their clinical trials.

Newly released data from the open-label extension of the FIREFISH study confirmed sustained safety and efficacy of Evrysdi in children with type 1 spinal muscular atrophy over 5 years.

The AMA House of Delegates adopted two new policies aiming to reform prior authorization and the burden it causes patients and physicians.